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Background: Activities to decrease the burden of tuberculosis (TB) among people living with HIV (PLHIV) include
intensified TB case-finding (ICF), Isoniaizid (INH) preventive therapy (IPT) and infection control in health-care and
congregate settings (IC). Information about the status of collaborative TB/HIV care services which decreases the
burden of TB among PLHIV in Ethiopia is limited. The purpose of the study was to assess TB case finding and
provision of IPT among PLHIV in Addis Ababa.
Methods: A cross sectional, facility-based survey was conducted between June 2011 and August 2011. Data was
collected by interviewing 849 PLHIV from ten health facilities in Addis Ababa. Both descriptive and inferential
statistics were used to analyze findings and the results are described in this report.
Results: The proportion of PLHIV who have been screened for TB during any one of their follow-up cares was
92.8%. Eighty eight (10.4%) of the study participants have been diagnosed for TB during their HIV follow-up cares.
PLHIV who had never been diagnosed for TB before they knew their positive HIV status were nearly four times more
likely to be diagnosed for TB during follow-up cares than those diagnosed before (AOR [95% CI]: 3.78 [1.69-8.43]).
Nearly a third (28.7%) of all interviewed PLHIV self reported that they had been treated with IPT.
Conclusions: It can be concluded that ICF for TB and IPT among PLHIV in Addis Ababa need boosting. Hence, it is
recommended to put into practice the national and global guidelines to improve ICF and IPT among PLHIV in the
city.
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The dramatic spread of HIV in the past few decades, par-
ticularly in sub-Saharan Africa, has been accompanied by
a major increase in the number of new cases of tubercu-
losis (TB) [1]. In 2010, TB killed an estimated 1.68 million
people, including 0.38 million deaths among TB patients
who were HIV positive [2].
The proportion of TB and HIV co-infection is highest in
African countries. Overall, the African region accounted
for 82% of TB cases among people living with HIV* Correspondence: denegetu@gmail.com
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distribution, and reproduction in any medium(PLHIV) [3]. According to the global fund to fight
AIDS, TB and malaria (GFATM) information note, the
interaction between TB and HIV presents additional
challenges to TB control. It is crucial to improve and
strengthen TB/HIV collaborative activities to reduce
the burden of TB in PLHIV and reduce the burden of
HIV among TB patients [1].
Collaborative TB/HIV management is essential to en-
sure that HIV positive TB patients are identified and
treated appropriately, and to prevent TB in HIV positive
people. Activities to decrease the burden of TB among
HIV patients include intensified TB case finding (ICF),
for those without active TB, INH preventive therapyed Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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gregate settings [4,5].
According to the World Health Organization (WHO)
[5] document recommendation, ICF for TB means regu-
larly screening all people with or at high risk for HIV in-
fection, or in congregate settings (such as mines, prisons,
military barracks) for the symptoms and signs of TB,
followed by prompt diagnosis and treatment. The most
efficient approach to detecting more cases and with
shortened duration of infectivity involves intensified
case-finding in settings where HIV-infected people are
concentrated.
The same document [5] recommends that IPT for TB
can be safely given to PLHIV without TB, reducing the
risk of developing TB by 33-67% for up to 48 months. It
is currently recommended for all PLHIV in areas with a
prevalence of latent TB infection >30%, and for all
PLHIV with documented latent TB infection or expos-
ure to an infectious TB case, regardless of where they
live.
Information about the status of collaborative TB/HIV
care services which decreases the burden of TB among
PLHIV in Ethiopia is limited. Hence, the purpose of this
study is to assess ICF for TB and IPT among PLHIV at
public health facilities of Addis Ababa, Ethiopia.
Research objectives
General objective
 To assess collaborative TB/HIV care services
decreasing the burden of TB among PLHIV in Addis
Ababa, Ethiopia.
Specific objectives
 To determine the proportion of PLHIV attending
HIV care clinics who were screened for TB.
 To determine the proportion of PLHIV attending
HIV care clinics who were diagnosed for TB during
their follow-up cares.
 To determine the proportion of PLHIV who have




This is a cross sectional, facility-based descriptive study
which was conducted at two referral hospitals and eight
health centres in Addis Ababa City, Ethiopia. One health
facility from each of the ten sub-cities of the city was se-
lected randomly and two hospitals were included con-
veniently out of the five referral hospitals administered
under Addis Ababa City Administration Health Bureau.Settings
The study setting includes ZewdituMemorial andMenelik
II hospitals which are HIV therapy and care referral hos-
pitals, and ten health centres, namely: Lideta, Yeka,
Kazanchis, Nifas-Silk Lafto No-1, Woreda 7, Kality, Bole
and Gulele. The health facilities were used to assess the
implementation of ICF for TB and provision of IPT
among PLHIV attending HIV care clinics.
Study participants
The study participants include PLHIV who were regis-
tered at HIV clinics and on their follow-up cares in the
health facilities. In this study, children under the age of
15 were not included.
Sampling method
The sample size was determined using single population
proportion formula. A 50% TB/HIV co-infection was es-
timated for Addis Ababa aiming for maximum sample
size, with marginal error of 5% and 95% confidence
interval. The calculated sample size was 384.
n ¼ Z α
2
2
 p 1−pð Þ
d2
¼ 1:96ð Þ
2  0:5 0:5ð Þ
0:0025
¼ 384
To eliminate the design effect, the sample size was
doubled and 10% of the total sample size was added as
contingency. Hence, the total sample size used in this
study become (384 × 2) + 10% = 845. Randomly selected
PLHIV attending HIV care clinics at the selected health
facilities in their follow-up cares were interviewed at exit.
In this study, the researcher used probability propor-
tional to size (PPS) of cumulative HIV patient load in the
facilities to determine the sub-samples for each of the
sites. It was confirmed from HIV registration books that,
the patient load in health centres on average was less
than the load in the hospitals. In addition, the commuta-
tive load of patients among the different health centres
was similar and that for hospitals was also similar. There-
fore, the researcher decided to take an equal number of
sub-samples from each of the eight health centres and
also equal number from the two hospitals. But the sam-
pled population from the health centres was less than the
samples from the hospitals as reasoned above.
According to the health facilities HIV registration
books, the study health centres and hospitals had on aver-
age 1120 and 1435 cumulative HIV patients at the time of
the study; respectively. Hence, based on PPS method, the
calculated sampled population for each of the health cen-
tres was 80 and that for the hospitals was 103.
Data collection
The data collection was done from June 2011 to August
2011. The questionnaire was administered using experienced
Table 1 Collaborative TB/HIV care service deliveries
among people living with HIV in Addis Ababa
Variable Frequency Percent
TB screening offered at HIV care clinic
Yes 788 92.8
No 31 3.7
I do not know 30 3.5
Total 849 100.0
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WHO guideline, prepared for monitoring and evaluation
of TB/HIV activities [6]. The questionnaire has accept-
able levels of reliability and is valid for the Ethiopian
situation. This is because, the questionnaire is adapted
directly from the global TB/HIV monitoring Interview
Tool [6] which is in-line with the global policy on collab-
orative TB/HIV activities [4] and national TB/HIV collab-
orative activity guideline [7]. In addition, the researchers
believe that the questionnaire is reliable as data was
collected by direct interview of HIV patients after their
consent and reassurance of confidentiality. In addition,
the interviews were conducted by sociologists who have
no direct relation with the healthcare system and hence
reduce professional bias.
Ten data collectors administered the questionnaires
simultaneously during the data collection period. The
principal investigator provided daily supportive supervi-
sion to all data collectors by checking the completeness
and consistency of the filled questionnaires. Study par-
ticipants were enrolled randomly for the interview on
exit for consecutive days until the allotted sample size
filled for that particular facility. One data collector was
assigned for one health facility, and a maximum of 10
interviews were conducted per facility per person per
day to maintain the quality of the data.
For this study, the questionnaire was pre-tested on 12
participants by each of the data collectors from two
health centres. The pre-test data was collected from facil-
ities not included for this study.
Ethical clearance was obtained from the University of
South Africa and the Addis Ababa City Administration
Health Bureau. A support letter from the Addis Ababa
City Administration Health Bureau and permission was
obtained from heads of each of the study health facilities.
The interview was undertaken after ascertaining written
consents from each study participant. The questionnaire
did not include any specific identifier of the interviewee.
Data analysis
The Statistical Package for Social Sciences (SPSS) version
15.0 was used for data capturing and analysis. Both de-
scriptive and inferential statistics were used for present-
ing the findings. Logistic regression was used to identify
factors associated with TB case finding across the various
independent variables including; sex, marital status, edu-
cational status, length of being diagnosed for TB and on
HAART and previous history of TB disease.
Results
A total of 849 PLHIV, who were under HIV care follow-
ups at public health facilities in Addis Ababa City
Administration, participated in the study. Out of the
total respondents 592(69.7%) were females.The mean age (± SD) of the study population was 33.9 ±
9.9 years. Six hundred and fifty eight (77.4%) of the partic-
ipants were in the age group 25–49, 415 (48.9%) were
married and 198 (23.3%) were singles, 701 (82.6%) were
followers of Christian religion. Around 38.2% had com-
pleted high school study, 9.40% had at least a certificate
after completing high school. The remaining 29.1% and
23.2% accounted for primary completed and having no
formal education at the time of the study; respectively.
Two hundred twenty five (26.5%), 168 (19.8%), 159
(18.7%) and 153 (18.0%) were unemployed, house wives,
self employed and privately employed, by occupation; re-
spectively. Nearly three-fourth (74.6%) of the study partic-
ipants had become at least one year since they knew their
HIV positive status. Seven hundred and five (83%) of
these clients had already started Anti-Retroviral Therapy
(ART) in the health facilities. Of those put under highly
active antiretroviral therapy (HAART), 451 (63.9%) were
on ART for more than one year.
Screening for tuberculosis
The proportion of interviewed PLHIV who have been
screened for TB during any one visit of their follow-up
cares was 92.8% (788) (Table 1). The result revealed that,
3.7% (31) of participants have self reported that they had
never been screened for TB. Besides, 3.5% (30) of inter-
viewed PLHIV could not be sure whether they were
screened for TB disease or not; this of course, can be as-
sociated with patients’ knowledge on their health ser-
vices or poor communication of healthcare providers.
Prevalence of tuberculosis among people living with HIV
As TB is one of the first opportunistic infection for
PLHIV, screening of all HIV positive patients for TB
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10.4% (88) of study participants have self reported that
they were diagnosed for active TB disease during their
HIV care follow-ups (see Table 1). In other words, 88 ac-
tive TB patients were identified out of the total 849
PLHIV starting from their first contact to the healthcare
provider for either of HIV testing, care or treatment
services.
Results of multiple logistic regression with stepwise
selection show that those who were on HAART for more
than one year were nearly four times more likely to be
diagnosed for TB than those who were on HAART for
less than six months, and the result was statistically sig-
nificant [AOR (95%CI): 3.53(1.17-10.65)]. Similarly, those
who had never been diagnosed for TB before they knew
their HIV status were nearly four times more likely to be
diagnosed for TB during follow-up cares than those diag-
nosed before, the results were also statistically significant
[AOR (95%CI): 3.78(1.69-8.43)] (Table 2).
On the other hand, univariate analysis revealed that,
those who have become >3 years since they knew their
HIV positive status were nearly 3 times more likely to
be diagnosed for TB than those who became less than
6 months, [Unadjusted OR (95%CI): 2.67(1.17-6.08)]
(Table 2).
Isoniazid preventive therapy
Nearly a third 28.7% (244) of all interviewed PLHIV self
reported that they had been treated with IPT (Table 1).
Logistic regression analysis of INH preventive therapy
among the various independent variables did not show
any association.Table 2 Tuberculosis case finding among people living with H
Variable Ever been diagnosed for TB after HIV
Yes (88) No
How long have you been diagnosed for HIV?
Less than 6 months 7
6 -11 months 5
1-3 years 30
More than 3 years 46
How long have you been on HAART?
Less than 6 months 7
6 months-1 year 9
More than 1 year 63
Not yet started 9
Ever been diagnosed for TB before HIV-positive
Yes 7
No 79
Do not remember 2
n = 849.Discussion
HIV infection is the most powerful known risk factor for
progression of Mycobacterium TB infection to active dis-
ease; increasing the risk of latent TB reactivation by 20-
fold [8]. Therefore, simple questionnaires to screen for
TB can be administered when people seek HIV services
for the first time (e.g., voluntary counselling and testing,
HIV care, etc.) and/or by community based organizations
supporting people with HIV. ICF serves as the most im-
portant gatekeeper for the two other I’s (infection control
and Isoniazid preventive therapy), facilitating rapid iden-
tification of TB suspects (allowing for triage and other
steps to reduce TB transmission), and acting as the ne-
cessary first step for healthcare providers to confidently
prescribe IPT to PLHIV who do not have active TB [5].
According to the global TB report of 2011, in 2010,
2.3 million PLHIV were screened for TB (up from 1.7
million in 2009) and 178,000 of those without active TB
were enrolled for IPT (double the level achieved in
2009) [3]. The number of PLHIV who were screened for
TB was equivalent to more than half (58%) of the re-
ported number of people who were enrolled in HIV care
worldwide in 2010. The number started on IPT was 12%
(178 144/1 464 579) of the reported number of PLHIV
newly enrolled in HIV care in 2010 [3].
In this study 92.8% of PLHIV have self reported that
they had been screened for common signs and symp-
toms for TB by their healthcare providers (more than 2
weeks of cough, night sweats, weight loss and weakness).
This result is slightly higher than that of an earlier study
in the same place by Wesen and Mitike that shows
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sult is higher than findings from previous studies in
other African countries. For example, a study on integra-
tion of TB and HIV services in Sub-Saharan Africa by
Andrea and Wafaa in 2010 shows that, 64% of newly
enrolled persons with HIV infection or AIDS in the first
quarter of 2009 were screened for TB. An average of
22% of these patients screened positive for TB, of whom
an average of 12% received a diagnosis of TB and initi-
ated treatment [10].
In addition, persons with HIV infection or AIDS remain
at risk of TB throughout the course of their HIV disease,
including after ART initiation [11,12]. Thus, screening for
TB should be done routinely during each follow-up cares.
Performance of TB screening at every clinical encounter
can be challenging in resource-constrained environments,
particularly at sites that serve large numbers of persons
with HIV infection or AIDS and where continuity care is
a new paradigm [10].
The steady improvement in proportion of PLHIV
screened for TB in Addis Ababa (from 89.7% in 2008 [8]
to 92.8% in the present study) is also consistent with
findings from a study in South Africa. A study at 9 HIV
care and treatment centres in Nelson Mandela Bay
District, Eastern Cape shows that the proportion of newly
enrolled persons with HIV infection or AIDS who were
screened for TB increased from 73% in the first half of
2007 to 95% in the latter half of 2008, after the introduc-
tion of a clinical record that incorporated TB screening
questions [13].
Besides, this finding is similar to an earlier national re-
port. According to the progress report of the Federal
Democratic Republic of Ethiopia towards the implemen-
tation of the UN Declaration of Commitment on HIV/
AIDS, the proportion of HIV-positive patients who were
screened for TB increased from 25% in 2007 to 55% in
2009 for the country [14].
Escalating TB case rates over the past few decades in
many countries in sub-Saharan Africa and in parts of
South East Asia are largely attributable to the HIV epi-
demic. Since mid-1980s, in many African countries, in-
cluding those with well-organized programs, annual TB
case notification rates increased by four fold, reaching
peaks of >400 cases/100,000 populations [4].
The result in this study shows that 10.4% of PLHIV
developed active TB during HIV follow-up cares. But pre-
vious finding from a similar study in the same place
(Addis Ababa) in 2008 [9] was slightly higher (15.6%) than
the current prevalence. Hence, this decrement through
time might be attributed to the improvements in HIV
treatment and care services in Addis Ababa.
However, the finding in this study for the prevalence
of TB among PLHIV is very low compared to findings
elsewhere. For example, a study in Hong Kong in 2005reveals a prevalence of 39% [15]. In another study in
Karachi, Pakistan, in 2007, the prevalence of TB among
HIV patients is 30.2%, though the setting is different
[16]. A study in Georgia in 2008 also shows a higher
prevalence of TB among PLHIV; up to 22% of HIV posi-
tive individuals have active TB [17].
On the other hand, this study revealed that the probabil-
ity of being diagnosed for TB is increasing the longer pa-
tients are on HAART; i.e., those who became more than
one year on HAART were nearly four times more likely to
be diagnosed for TB than those of less than six months.
This finding is in contrary to the fact that ART is one of
the most potent tools for preventing HIV-associated TB,
as evidenced in previous studies [18,19]. Hence, this may
not be fully explained in this study. But, the finding can be
consistent with the low coverage of IPT (28.7%); whereby,
majority of PLHIV have no access to TB prophylactic
therapy. However, an earlier study reveals that, initial
reduction for the risk of TB is not apparent [20].
Isoniazid Preventive Therapy for TB can safely be
given to PLHIV without active TB disease, reducing the
risk of developing TB by 33-67% for up to 48 months. It
is currently recommended for all PLHIV in areas with a
prevalence of latent TB infection >30%, or for all PLHIV
with documented latent TB infection or exposure to an
infectious TB case, regardless of where they live [5].
In addition, the efficacy of IPT has been well docu-
mented in the prevention of at least the first episodes of
TB among PLHIV in different studies. For example, a
meta-analysis by Woldehanna and Volmink [21] shows
that the provision of IPT to persons with HIV infection
even in the absence of ART reduced the incidence of TB
by 33% overall and by 64% among individuals with posi-
tive tuberculin skin test (TST) results, compared with
placebo. Besides, observational studies suggest that IPT
reduces the risks of TB and death during early ART [22]
and that IPT and ART in combination result in a greater
reduction in TB risk than does either treatment alone
[22,23].
Despite these evidences, implementation of IPT in HIV
care and treatment programs in resource-constrained
countries has been documented to be unacceptably low
[24].
The finding from this study is not very far from this
fact. The study revealed that less than a third (28.7%) of
all PLHIV interviewed had been enrolled for IPT during
their follow-up cares. However, the finding of this study
is higher than previous findings from other countries
and even in Ethiopia. For example, according to the
2011 global TB report [3], sampled data for Bangladesh
revealed IPT coverage of only 5.4%, for Ethiopia 15.1%,
for Myanmar 8.0%, and only 3% for Nigeria.
In general, provision of IPT among PLHIV is linked to
operational challenges and Ethiopia is not exceptional.
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test (TST) for PLHIV before enrolled to IPT. However,
the use of TST could reduce the number of patients re-
ceiving IPT and the numbers needed to treat to prevent
one case of active TB [25]. The other reason for the low
coverage IPT in the current study could be fear of drug
resistance by some clinicians, as evidenced in a previous
report [26], which is in contrary to the WHO recom-
mendation of IPT provision, reaffirming concerns re-
garding the development of drug resistance should not
be a barrier to providing IPT [25].
This study did not include exploratory qualitative data
and might introduce recall bias, as findings are dependent
on patients’ self report, which can be considered as a limi-
tation. However, the use of a maximum sample popula-
tion and doubling the design effect coupled with the use
of social science professionals for data collection to re-
duce professional bias can be considered as the strengths
of the study.
Conclusion
It can be concluded that screening for TB among PLHIV
in Addis Ababa is being done optimally. Prevalence of TB
among PLHIV seems low compared to previous findings
both in Ethiopia and in other countries; which could not
be explained in this study. In addition, provision of IPT is
still low, though better than previous studies. Hence, ICF
for TB and IPT among PLHIV in Addis Ababa, Ethiopia
need boosting by adopting the available national and
international guidelines. In addition, continuous support
of healthcare providers through on-going trainings and
experience sharing forums can be used as a tool for im-
proving the implementation of ICF and IPT.
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